ORIC Pharmaceuticals
ORICNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $8.91 Prior regular-session close from the quote source.
- $8.84–$9.15 Regular-session low and high so far today.
- 773.3K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Nov 12 projected Projected for 2026-11-12 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $7.23–$14.68 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own ORIC if ORIC is a high-risk clinical-stage oncology option whose value depends on proving that its focused approach to overcoming resistance in cancer can generate differentiated clinical data before financing dilution consumes the upside.
ORIC price history
Loading recent earnings…
Investment thesis
What must happen next
ORIC’s oncology-resistance focus creates value only if its programs show differentiated patient benefit versus existing cancer standards, not merely scientific plausibility.HoldingMateriality: High
The company is described as a clinical-stage biopharmaceutical company focused on delivering innovative medicines that aim to overcome resistance in cancer. If this holds, ORIC can attract partner, acquirer, regulatory, or investor capital; if it breaks, the equity becomes a cash-burn vehicle without a defendable asset.
Watch: Clinical readouts show ORIC’s candidates do not improve response, durability, safety, or tolerability enough versus current standards of care.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company is described as a clinical-stage biopharmaceutical company focused on delivering innovative medicines that aim to overcome resistance in.
Open source ↗Runway is a core competitive asset: ORIC must finance clinical value-inflection from strength rather than raise capital only after delays or weak data.HoldingMateriality: High
GAAP cash and cash equivalents were $45.7 million at FY2025 year-end, down from $59.4 million at FY2024 year-end. Strong runway lets shareholders keep more of any clinical upside; weak runway shifts value to new investors through discounted financing.
Watch: ORIC must raise equity after a weak clinical update or during a closed biotech financing window.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP cash and cash equivalents were $45.7 million at FY2025 year-end, down from $59.4 million at FY2024 year-end.
Open source ↗ORIC’s focused development model must keep cash burn predictable while advancing trials, because it has no visible self-funding commercial engine in the supplied data.HoldingMateriality: Medium
GAAP annual operating cash flow was negative $111.0 million in FY2025, roughly in line with negative $112.7 million in FY2024. Predictable burn preserves the option value of clinical programs; uncontrolled burn shortens runway and raises the odds of dilution before proof-of-concept.
Watch: Late-stage trial starts, manufacturing commitments, or expanded clinical sites cause burn to accelerate before the next value-creating data event.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was negative $111.0 million in FY2025, roughly in line with negative $112.7 million in FY2024.
Open source ↗A low fixed-obligation balance sheet should let ORIC choose development and partnership timing based on data rather than creditor pressure.StrengtheningMateriality: Medium
GAAP total liabilities were $24.5 million at FY2025 year-end. Low leverage makes clinical optionality more valuable to shareholders; creditor constraints would force capital allocation at the wrong time.
Watch: ORIC takes on restrictive debt or royalty financing that limits strategic flexibility.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP total liabilities were $24.5 million at FY2025 year-end.
Open source ↗ORIC’s small specialist organization must translate scientific focus into fast, disciplined clinical execution; key talent loss or inability to recruit would impair the value-creation engine.HoldingMateriality: Medium
ORIC had 104 full-time employees as of December 31, 2025. For a clinical-stage biotech, the team is the operating system; execution failures can destroy value before any revenue opportunity exists.
Watch: Departure of senior scientific, clinical, regulatory, or business-development leaders slows programs or weakens trial design.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
ORIC had 104 full-time employees as of December 31, 2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
ORIC’s oncology-resistance focus creates value only if its programs show differentiated patient benefit versus existing cancer standards, not merely scientific plausibility. If this holds, ORIC can attract partner, acquirer, regulatory, or investor capital; if it breaks, the equity becomes a cash-burn vehicle without a defendable asset.
Runway is a core competitive asset: ORIC must finance clinical value-inflection from strength rather than raise capital only after delays or weak data. Strong runway lets shareholders keep more of any clinical upside; weak runway shifts value to new investors through discounted financing.
ORIC’s focused development model must keep cash burn predictable while advancing trials, because it has no visible self-funding commercial engine in the supplied data. Predictable burn preserves the option value of clinical programs; uncontrolled burn shortens runway and raises the odds of dilution before proof-of-concept.
A low fixed-obligation balance sheet should let ORIC choose development and partnership timing based on data rather than creditor pressure. Low leverage makes clinical optionality more valuable to shareholders; creditor constraints would force capital allocation at the wrong time.
ORIC’s small specialist organization must translate scientific focus into fast, disciplined clinical execution; key talent loss or inability to recruit would impair the value-creation engine. For a clinical-stage biotech, the team is the operating system; execution failures can destroy value before any revenue opportunity exists.
All standing thesis claims
Original report summary
ORIC is a high-risk clinical-stage oncology option whose value depends on proving that its focused approach to overcoming resistance in cancer can generate differentiated clinical data before financing dilution consumes the upside.
Bull case and bear case
Bull case and bear case for ORIC Pharmaceuticals
Where the evidence on ORIC Pharmaceuticals stands: Holding on the latest evidence (Oct 20, 2026). Of its 5 thesis points, 1 strengthening and 4 holding.
Bull case: what the evidence supports
ORIC’s oncology-resistance focus creates value only if its programs show differentiated patient benefit versus existing cancer standards, not merely scientific plausibility.
Runway is a core competitive asset: ORIC must finance clinical value-inflection from strength rather than raise capital only after delays or weak data.
ORIC’s focused development model must keep cash burn predictable while advancing trials, because it has no visible self-funding commercial engine in the supplied data.
A low fixed-obligation balance sheet should let ORIC choose development and partnership timing based on data rather than creditor pressure.
ORIC’s small specialist organization must translate scientific focus into fast, disciplined clinical execution; key talent loss or inability to recruit would impair the value-creation engine.
Bear case: what would count against it
Clinical readouts show ORIC’s candidates do not improve response, durability, safety, or tolerability enough versus current standards of care.
ORIC must raise equity after a weak clinical update or during a closed biotech financing window.
Late-stage trial starts, manufacturing commitments, or expanded clinical sites cause burn to accelerate before the next value-creating data event.
Thesis-Break Engine
Thesis-break watch · ORIC Pharmaceuticals
No break has crossed ORIC Pharmaceuticals’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
ORIC Pharmaceuticals filed an SEC 8-K on 2026-08-03: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
ORIC Pharmaceuticals filed an SEC 8-K on 2026-07-30: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
ORIC Pharmaceuticals filed an SEC 8-K on 2026-06-22: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Clinical readouts show ORIC’s candidates do not improve response, durability, safety, or tolerability enough versus current standards of care.
- ORIC must raise equity after a weak clinical update or during a closed biotech financing window.
- Late-stage trial starts, manufacturing commitments, or expanded clinical sites cause burn to accelerate before the next value-creating data event.
- ORIC takes on restrictive debt or royalty financing that limits strategic flexibility.
- Departure of senior scientific, clinical, regulatory, or business-development leaders slows programs or weakens trial design.
ORIC news
Loading headlines…
Financial statements
ORIC income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
ORIC: quick answers
- When does ORIC Pharmaceuticals (ORIC) report earnings next?
- ORIC Pharmaceuticals's next results are projected for November 12, 2026, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on August 3, 2026. Earnings calendar
- What is ORIC's short interest?
- As of October 30, 2026, 10.7M ORIC shares were sold short, 10.3% of its shares outstanding, down 30.4% from the count before. At the stock's average daily volume that is 4.8 days to cover. FINRA publishes the count twice a month. ORIC short interest history
- Which well-known investors own ORIC?
- 1 of the 37 well-known funds tracked here reported ORIC shares in their latest 13F filing. By share of the fund's portfolio: Viking Global Investors (Andreas Halvorsen), 0.2%. Fund portfolios
ORIC in well-known investors’ portfolios
1 of 37 funds reported ORIC shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Andreas HalvorsenViking Global Investors | 0.16% | $55.5M | −12.0% | Q2 2026 |